Studies suggest that there is no protection against SARS-CoV-2 infections from recent exposure to HCoVs
-2.jpg?fit=300%2C300&ssl=1 "Results of a phase 2 trial of the Novavax reconstituted SARS-CoV-2 nanoparticle vaccine")
.jpg?fit=300%2C300&ssl=1 "Genetic mutation associated with COVID-19 production")
-1.jpg?fit=300%2C300&ssl=1 "Pfizer SARS-CoV-2 vaccine effective from day 11 after 1d vaccine")
.jpg?fit=300%2C300&ssl=1 "Study showing long-term neuropsychological effects after SARS-CoV-2 infection")